Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.

We compared clinical disease progression in 159 human immunodeficiency virus (HIV)-infected persons for whom highly active antiretroviral therapy (HAART) was initiated when they had CD4(+) T lymphocyte counts of 350-499 cells/mm(3) with progression in 174 HIV-infected patients for whom it was not. Disease progression did not differ between the 2 groups (P=.21, log-rank test). Fifty-three percent of the 159 treated patients had HIV type 1 RNA levels of >400 copies/mL at the most recent evaluation, and 41% had experienced adverse drug reactions necessitating a change in regimen. These findings support the recommendation that HAART not be initiated for patients with CD4(+) cell counts of >350 cells/mm(3).

[1]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[2]  Julio S. G. Montaner,et al.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.

[3]  J. Fellay,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[4]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[5]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[6]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[7]  R. Weber,et al.  Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l , 2002, AIDS.

[8]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[9]  J. Chmiel,et al.  Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients , 2002, AIDS.

[10]  R. Chaisson,et al.  Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort , 1996, Annals of Internal Medicine.

[11]  R Weber,et al.  HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. , 2001, JAMA.

[12]  John W. Mellors,et al.  Panel on Clinical Practices for Treatment of HIV Infection , 2000 .

[13]  Richard D Moore,et al.  HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy , 2001, AIDS.